08.26 (Tuesday) |
The Platz Hall Glass Matchmaking Room (#PE17) |
P-1 |
14:00 - 15:00 |
Technology transfer seminar - Introduction of promising technologies using biological resource |
National Institute of Biological Resources (NIBR) & Nakdonggang National Institute of Biological Resources (NNBIR) & Honam National Institute of Biological Resources (HNIBR) & National Institute of Ecology (NIE) |
K |
14:00 - 14:15 |
A patent for skin-improving use with bio-transformation products of plant extracts as active ingredients |
National Institute of Biological Resources (NIBR) |
Wonjae Ji, Researcher |
14:15 - 14:30 |
Production of high-purity freshwater Diatom Biosilica for drug delivery applications |
Nakdonggang National Institute of Biological Resources (NNBIR) |
Daeryul Kwon, Associate Researcher |
14:30 - 14:45 |
Development and Commercialization Research of Biomaterials Derived from Coastal Marine Biological Resources |
Honam National Institute of Biological Resources (HNIBR) |
JungUp Park, Senior Researcher |
14:45 - 15:00 |
Utilization of Biomimicry Knowledge Information Systems for Promoting the Bioindustry |
National Institute of Ecology (NIE) |
Seungwoo Sim, Associate Researcher |
The Platz Hall Seminar Room (2F) |
P-2 |
13:30 - 15:30 |
DIPS Open Innovation Day - Challenges and Tasks for Building K-BIO's Global Collaboration Ecosystem |
Korea Institute of Toxicology (KIT) |
|
13:30 - 14:30 |
K-BIO: Where we are? Where we want to be? And, how do we get there? |
AMC Biosciences, Partner of Shimbio |
Dr. Cho Ho Seong, BOD member |
K |
Invited Presentation Market entry procedures for Saudi Arabia and SFDA requirements |
All Care Medical Industries |
Mr. Sultan Abdullah Al Mansour, Chairman of AllCareGroup for Investment |
E |
Open Innovation Performance |
|
|
K |
14:30 - 15:30 |
Supply Technology Presentation |
|
|
K |
13:30 - 17:00 |
<Large and mid-sized pharmaceutical and bio companies - DIPS companies Partnering>
* Pre-matching/ Location will to be confirmed |
Korea Institute of Toxicology (KIT) |
K |
08.27 (Wednesday) |
The Platz Hall Seminar Room (2F) |
P-3 |
10:20 - 12:30 |
Current Landscape and Future Prospects of the Exosome Industry |
Extracellular Vesicles Industry Association (EVIA) |
K |
10:20 - 10:40 |
Exosome Technology in Aesthetics and Regenerative Medicine: Current Landscape, Challenges, and Future Prospects |
ExoCoBio Inc. |
Byong Seung Cho, CEO/CTO |
10:40 - 11:00 |
Precision EV Isolation: Accelerating Therapeutic Breakthroughs with LabSpinner Technologies |
LabSpinner Inc. |
Kyusang Lee, CEO |
11:00 - 11:20 |
Exosome Innovation and Clinical Translation: Unlocking New Therapeutic Possibilities |
S&E bio Co., Ltd. |
Eun Hee Kim, CTO |
11:20 - 11:40 |
EV Cargo Control via Preconditioning: Enhancing Therapeutic Potential |
Brexogen Inc. |
SeungtTaek Oh, EVP |
11:40 - 12:00 |
Nonclinical and Clinical trial of First-in-class anti-inflammatory exosome therapeutics |
ILIAS Biologics Inc. |
Chulhee Choi, CEO |
12:00 - 12:30 |
<Panel Discussion: Current Landscape and Future Prospects of the Exosome Industry> |
Panel Moderator: Shingyu Bae (Mdimune)
Panels: Byong Seung Cho (ExoCoBio Inc.), Kyusang Lee (LabSpinner Inc.), Eun Hee Kim (S&E bio Co., Ltd.), Oh, SeungtTaek (Brexogen Inc.), Chulhee Choi (ILIAS Biologics Inc.)
|
P-4 |
13:00 - 14:30 |
Strengthening Biopharmaceutical Supply Chains: Strategies for Raw Material Localization |
Korea Biomedicine Industry Association (KoBIA) |
K |
13:00 - 13:10 |
Part 1 Policies to Support the Development and Commercialization of Domestic Raw and Auxiliary Materials |
13:00 - 13:10 |
Biopharmaceutical Raw Materials Commercialization Support Project |
Korea Conformity Laboratories (KCL) |
Sung Min You, Head of Center |
13:10 - 13:50 |
Part 2 Case Studies on the Commercialization of Domestic Raw and Auxiliary Materials |
13:10 - 13:30 |
Successful cases of Bio-consumbables Commercialization: Cell Culture Media & Purification Resin |
Amicogen |
Su-Lim Choi, Head of R&D |
13:30 - 13:50 |
Startup's Challenge to Localize Bioprocess |
UMTR Co.,Ltd. |
Sungryul Park, CEO |
13:50 - 14:30 |
Part 3 <Panel Discussion: Key Challenges and Strategies for Strengthening the Competitiveness of Domestic Raw and Auxiliary Materials> |
Panel Moderator: Youngbin Baek (Inha University)
Panels: Sung Min You (Korea Conformity Laboratories), Su-Lim Choi (Amicogen), Sungryul Park (UMTR), Yoon Hee-Jeong (Korea Institute of S&T Evaluation and Planning), Kim Hyung-cheol (Korea Planning & Evaluation Institute of Industrial Technology) |
P-5 |
15:30 - 17:00 |
Patient-Centered Innovation Strategies to Conquer Intractable Diseases |
Korea Biomedicine Industry Association (KoBIA) & K-Health MIRAE Initiative (Korean ARPA-H Project) & Hit Media Panel Moderator: Yoonbin Kim, PM of K-Health MIRAE Initiative (Korean ARPA-H Project) |
K |
15:30 - 15:55 |
Patient Engagement in Medical Product Development and Regulatory Decision-making |
Sungkyunkwan University |
Mihai Park, Research Professor |
15:55 - 16:15 |
Innovative, Patient-Tailored Strategy for Rare Disease Drug Development HEART and BEACON |
K-Health MIRAE Initiative (Korean ARPA-H Project) |
Misun Park, PM |
16:15 - 16:35 |
Implication of personalized cancer vaccine (PCV) R&D project based on the cutting-edge technology of Korea. |
Aston Sci. Inc. |
Jung, Hun, CEO |
16:35 - 16:55 |
Expected Benefits of Proactive Early Cancer Detection Enabled by Enhanced Patient Accessibility and Convenience |
IMBdx |
Tae-You Kim, CEO |
08.28 (Thursday) |
The Platz Hall Seminar Room (2F) |
P-6 |
10:00 - 12:30 |
DIPS Global IR Day |
Korea Institute of Toxicology (KIT) |
|
10:00 - 10:15 |
Topic Presentation Investment Attraction Strategy for K Bio Companies in a Time of Transition |
LSK Investment |
Myungkee Kim, CEO |
K |
10:15 - 10:30 |
US Biohealth Investment Trends and Implications |
Shimbio |
Kwangryong Yoo, CEO |
K |
10:30 - 10:45 |
Trends in bio investment in Europe, including the UK, and Korean companies' entry strategies |
SD&k |
Minsik Gong, CEO |
K |
10:45 - 11:00 |
Saudi’s Strategic Investment Proposal for K Bio companies in Partnership with All Care group |
AllCare Group |
Mr. Sultan Abdullah Al Mansour, Chairman of AllCareGroup for Investment |
E |
11:00 - 11:50 |
IR of DIPS companies |
|
|
K |
10:00 - 12:30 |
<Partnering with Global VCs and DIPS companies>
* Pre-matching/ Location will to be confirmed |
Korea Institute of Toxicology (KIT) |
K |
P-7 |
13:40 - 15:30 |
Pharmaceutical Industry Outlook in Ethiopia, Peru, and Uzbekistan – Policy Environment, Market Access, and Investment Incentives |
United Nations Industrial Development Organization (UNIDO) |
E |
13:50 - 14:20 |
Pharmaceutical Industry Outlook in Ethiopia – Policy Environment, Market Access, and Investment Incentives |
Ethiopian Pharmaceutical Supply Agency (EPSS) - Ethiopia |
Abdulkedir Gelgelo, Director General |
14:20 - 14:50 |
Pharmaceutical Industry Outlook in Peru – Policy Environment, Market Access, and Investment Incentives |
Lima Chamber of Commerce (CCL) |
Sandro Stapleton, Director of the Health Committee |
14:50 - 15:30 |
Pharmaceutical Industry Outlook in Uzbekistan – Policy Environment, Market Access, and Investment Incentives |
Embassy of the Republic of Uzbekistan in the Republic of Korea |
Rukhullo Zikrillaev, Counsellor on Trade and Economic Affairs |